Senior Fitness - Exercise and Nutrition for Aging Men and Women
FREE Article Feed for your website.
Home Ownership Magazine
Party Planning Information
Article Marketing Resources
Bio-Medical Research Article Database
Informative Articles on Life, Love and Happiness
Tutorials on Business to Writing
Famous Quotes from Famous People
Song Lyric Information
New US Patent Information
Comprehensive List of Content by Category
Online Auctions and Shopping Related Articles
Article Search
Most Recent Articles
Title: Fluid amplifier with media isolation control valve
Patent Number: 7,080,664 Issued on 07/25/2006 to Ayer

Title: Cytokine receptor zalpha11 polypeptides
Patent Number: 6,803,451 Issued on 10/12/2004 to Presnell,   et al.

Title: Combine tailings sensor system
Patent Number: 7,074,125 Issued on 07/11/2006 to Ho,   et al.

Title: Method for fabricating mask ROM with self-aligned coding
Patent Number: 6,821,684 Issued on 11/23/2004 to Yang,   et al.

Title: Protected display case
Patent Number: 6,802,576 Issued on 10/12/2004 to Shepherd

Title: Rain recycling system
Patent Number: 7,080,662 Issued on 07/25/2006 to Pratt

Title: Image processing apparatus
Patent Number: 6,816,193 Issued on 11/09/2004 to Kohashi,   et al.

Title: METHOD FOR PROTECTION OF DATA REPRODUCTION ACCORDING TO MEDIUM PROTECTION DATA AND FIRST AND SECOND APPARATUS PROTECTION DATA TO DETERMINE WHETHER MAIN DATA ARE REPRODUCED IN THEIR ENTIRETY, P
Patent Number: 6,816,549 Issued on 11/09/2004 to Sugahara

Title: Methods and systems for improving display resolution in achromatic images using sub-pixel sampling and visual error filtering
Patent Number: 6,807,319 Issued on 10/19/2004 to Kovvuri,   et al.

Title: Lens actuator, optical pickup unit and optical disk apparatus
Patent Number: 7,102,966 Issued on 09/05/2006 to Tanaka

Title: Reticle, exposure monitoring method, exposure method and manufacturing method for semiconductor device
Patent Number: 7,092,068 Issued on 08/15/2006 to Komine

Title: Variable frequency dewatering assembly
Patent Number: 6,802,940 Issued on 10/12/2004 to Frawley,   et al.

Title: Genes encoding proteins regulating the pH of vacuoles
Patent Number: 6,803,500 Issued on 10/12/2004 to Iida,   et al.

Title: Cellulose acetates and process for producing the cellulose acetates
Patent Number: 6,803,458 Issued on 10/12/2004 to Ozaki,   et al.

Title: Replacement vehicle fuel intake device
Patent Number: 7,080,671 Issued on 07/25/2006 to Watkins

Title: Bent extruded profile
Patent Number: 6,821,640 Issued on 11/23/2004 to Wullrich,   et al.

Title: Nanocomposite articles and process for making
Patent Number: 6,818,163 Issued on 11/16/2004 to Fibiger,   et al.

Title: Computer module with integrated cover latching and attachment mechanism
Patent Number: 6,801,434 Issued on 10/05/2004 to Gallarelli,   et al.

Title: Method for producing polyester resin particle dispersion material, method for producing polyester resin particles, and method for producing electrophotographic spherical toner
Patent Number: 6,821,703 Issued on 11/23/2004 to Uno,   et al.

Title: Process for manufacturing semiconductor integrated circuit device
Patent Number: 6,800,557 Issued on 10/05/2004 to Ohashi,   et al.

Title: Connector apparatus and method of coupling bioprocessor equipment to a media source
Patent Number: 7,080,665 Issued on 07/25/2006 to Whall

Title: Preparation of lithium phosphate catalysts
Patent Number: 6,803,491 Issued on 10/12/2004 to Shum

Title: Drive bracket structure
Patent Number: 6,801,427 Issued on 10/05/2004 to Gan,   et al.

Title: Method to improve properties of poly(trimethylene terephthalate) film
Patent Number: 6,818,160 Issued on 11/16/2004 to Visioli

Title: Adjustable pressure element, particularly for electric household appliances
Patent Number: 7,071,430 Issued on 07/04/2006 to Farano,   et al.

Title: Multiple function electronic cards
Patent Number: 7,097,108 Issued on 08/29/2006 to Zellner,   et al.

Title: Reduction of fusible links and associated circuitry on memory dies
Patent Number: 7,102,956 Issued on 09/05/2006 to Ayyapureddi,   et al.

Title: Electrical tubing control and remediation apparatus and method of use
Patent Number: 7,025,131 Issued on 04/11/2006 to Baugh,   et al.

Title: Low-voltage excited red phosphor and method of preparing the same
Patent Number: 6,818,154 Issued on 11/16/2004 to Yu,   et al.

Title: Method of manufacturing a semiconductor light emitting device utilizing a nitride III-V compound semiconductor substrate
Patent Number: 7,026,179 Issued on 04/11/2006 to Suzuki,   et al.

Title: Stacked microfeature devices and associated methods
Patent Number: 7,071,421 Issued on 07/04/2006 to Heng,   et al.

Title: Magnetic sensor, magnetic head and magnetic recording apparatus
Patent Number: 6,801,413 Issued on 10/05/2004 to Seyama,   et al.

Title: Spindle motor and data recording/reproducing apparatus with dynamic-pressure fluid bearing supporting shaft and ball bearing support rotor
Patent Number: 6,801,388 Issued on 10/05/2004 to Kayama,   et al.

Title: Light guiding plate manufacturing apparatus and light guiding plate manufacturing method
Patent Number: 6,818,157 Issued on 11/16/2004 to Kobayashi,   et al.

Title: Miniature endoscope with imaging fiber system
Patent Number: 6,863,651 Issued on 03/08/2005 to Remijan,   et al.

Title: Ultrafast sampler with coaxial transition
Patent Number: 7,084,716 Issued on 08/01/2006 to Agoston,   et al.

Title: Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups
Patent Number: 7,087,710 Issued on 08/08/2006 to Medsker,   et al.

Title: Immortalized human keratinocyte cell line
Patent Number: 6,884,595 Issued on 04/26/2005 to Allen-Hoffmann,   et al.

Title: Transmission with long ring planetary gearset
Patent Number: 7,029,417 Issued on 04/18/2006 to Borgerson,   et al.

Title: Life vest
Patent Number: 7,024,891 Issued on 04/11/2006 to Huang,   et al.

Title: Reduction of oxides in a fluid-based switch
Patent Number: 7,071,432 Issued on 07/04/2006 to Lindsey

Title: Enclosure system for electronic equipment concealable in a table top
Patent Number: 6,802,577 Issued on 10/12/2004 to Gershfeld

Title: METHOD OF AND SYSTEM FOR PRODUCING DIGITAL IMAGES OF OBJECTS WITH SUBTANTIALLY REDUCED SPECKLE-NOISE PATTERNS BY ILLUMINATING SAID OBJECTS WITH SPATIALLY AND/OR TEMPORALLY COHERENT-REDUCED PLA
Patent Number: 6,830,189 Issued on 12/14/2004 to Tsikos,   et al.

Title: Ink jet printing apparatus with ink level detection
Patent Number: 6,799,837 Issued on 10/05/2004 to Chen,   et al.

Title: Thread breakage detection device for sewing machine
Patent Number: 6,802,273 Issued on 10/12/2004 to Mizuno

Title: Method and apparatus for decreasing cable installation time and cable installation faults
Patent Number: 7,047,553 Issued on 05/16/2006 to Cloonan,   et al.

Title: System and method for linking an indicium with address information of a mailpiece in a closed system postage meter
Patent Number: 6,886,001 Issued on 04/26/2005 to Allport,   et al.

Title: Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
Patent Number: 6,803,385 Issued on 10/12/2004 to Klimko,   et al.

Title: Circuitry and method for accelerated switching of an amplifier
Patent Number: 7,084,706 Issued on 08/01/2006 to Minichshofer

Title: Polymeric urethane ester tertiary amines and related personal care formulations
Patent Number: 7,087,700 Issued on 08/08/2006 to Zofchak,   et al.

Title: Method and system for spatially compositing digital video images with a tile pattern library
Patent Number: 7,027,072 Issued on 04/11/2006 to Sadowski

Title: Diphenylmethane derivatives
Patent Number: 6,803,480 Issued on 10/12/2004 to Haning,   et al.

Title: Automatic biasing of a power device for linear operation
Patent Number: 7,084,705 Issued on 08/01/2006 to Prodanov

Title: Virtual path aggregation
Patent Number: 6,807,171 Issued on 10/19/2004 to Chow,   et al.

Title: Sulfonamide derivatives
Patent Number: 6,803,484 Issued on 10/12/2004 to Aikins,   et al.

Title: Instrument panel assembly for vehicle
Patent Number: 6,802,559 Issued on 10/12/2004 to Yoshihara,   et al.

Title: Apparatus and method for non-interactive electrophotographic development and carrier bead composition therefor
Patent Number: 6,821,700 Issued on 11/23/2004 to Lewis

Title: Portable containment system
Patent Number: 6,821,600 Issued on 11/23/2004 to Henson

Title: Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
Patent Number: 6,803,358 Issued on 10/12/2004 to Borgford

Title: Thin film transistor, method of producing the same, liquid crystal display, and thin film forming apparatus
Patent Number: 6,800,502 Issued on 10/05/2004 to Sung

Title: Collapsible barbecue apparatus
Patent Number: 6,802,308 Issued on 10/12/2004 to Nugent,   et al.

Title: Method for fabricating ruthenium thin layer
Patent Number: 6,800,542 Issued on 10/05/2004 to Kim

Title: Arrangement for switching data packets in a network switch based on subnet identifier
Patent Number: 6,807,176 Issued on 10/19/2004 to Egbert,   et al.

Title: Inhibitors of nucleoside metabolism
Patent Number: 6,803,455 Issued on 10/12/2004 to Furneaux,   et al.

Title: Apparatus for cleaning print head of ink jet printer
Patent Number: 6,802,590 Issued on 10/12/2004 to Lim

Title: Connector for positioning a pair of sunglasses or sunlenses in front of a pair of eyeglasses
Patent Number: 6,799,846 Issued on 10/05/2004 to Chow

Title: Airbag device and method of folding airbag
Patent Number: 6,830,266 Issued on 12/14/2004 to Abe

Title: Method of forming embedded MIM capacitor and zigzag inductor scheme
Patent Number: 6,800,534 Issued on 10/05/2004 to Hsieh

Title: Examination and treatment chair
Patent Number: 6,802,564 Issued on 10/12/2004 to Brockway,   et al.

Title: Method of making a bumped terminal in a laminated structure for a semiconductor chip assembly
Patent Number: 6,800,506 Issued on 10/05/2004 to Lin,   et al.

Title: Ink supply mechanism and inkjet recording apparatus including the ink supply mechanism
Patent Number: 6,799,840 Issued on 10/05/2004 to Inamura

Title: Buffer layers on metal alloy substrates for superconducting tapes
Patent Number: 6,800,591 Issued on 10/05/2004 to Jia,   et al.

Title: Method of forming insulating film and method of fabricating semiconductor device
Patent Number: 6,800,512 Issued on 10/05/2004 to Itonaga,   et al.

Title: Kite control bar with ninety-degree handles and fail-safe release system
Patent Number: 6,830,220 Issued on 12/14/2004 to Runyan

Title: Method and apparatus for tracking error detection in optical disk driver
Patent Number: 7,102,967 Issued on 09/05/2006 to Ma,   et al.

Lyophilized powder of lentinan and the process of preparation thereof Number:7,091,336 from the United States Patent and Trademark Office (PTO) owispatent

Home    Author Login    Submit Article    Article Search    Add Your Link    Edit Your Link    Contact Us    Advertising    Disclaimer

   

 
Web LinkGrinder.com

Top Breaking News
     US Ships in Frustrating Wait Off Burma's Coast to Deliver Aid by Luis Ramirez
     Global Warming Found to Cause Permanent Changes by Jessica Berman
     UN Security Council Supports Possible Peacekeepers for Somalia by Margaret Besheer

Title: Lyophilized powder of lentinan and the process of preparation thereof

Abstract: The present invention discloses an antineoplastic sterile lyophilized powder of lentinan and the process of preparation thereof. The lyophilized powder of lentinan is essentially consisted of 0.50 1.40 parts of lentinan and 50 140 parts of excipient for lyophilization, based on weight. It has good stability. It has improved safety as it does not contain dextran which may cause allergic side effect.

Patent Number: 7,091,336 Issued on 08/15/2006 to Cheng,   et al.


Inventors: Cheng; Pei Yuan (Jiangsu, CN), Weng; Jing (Jiangsu, CN), Fang; Yi Gong (Jiangsu, CN), Cheng; Guang (Jiangsu, CN)
Assignee: Nanjing Zhenzhong Bioengineering Co., Ltd. (Jiangsu, CN)
Appl. No.: 10/333,052
Filed: February 28, 2001
PCT Filed: February 28, 2001
PCT No.: PCT/CN01/00311
371(c)(1),(2),(4) Date: June 09, 2003
PCT Pub. No.: WO02/07708
PCT Pub. Date: January 31, 2002


Foreign Application Priority Data

Jul 19, 2000 [CN] 00 1 12407

Current U.S. Class: 536/123.1 ; 549/200
Current International Class: C07H 1/00 (20060101); A61K 31/335 (20060101)
Field of Search: 536/123.1,123.12 549/200 514/449


References Cited [Referenced By]

U.S. Patent Documents
5130127 July 1992 Herlyn
5648385 July 1997 Starrett et al.
Foreign Patent Documents
1076112 Sep., 1993 CN
1087610 Jul., 2002 CN

Other References

Seljelid, J., Scand. J. Immunol. 1989, 29: 181-92. cited by examiner .
Lee et al., Progress in Plant Polymeric Carbohydrate Research, 7th, berlin, Jul. 1-3, 1992 (12995) 77-80. cited by examiner .
Lee et al. Progress in Plant Polymeric Carbohydrate Research, 7th, Berlin, Jul. 1-3, 1992 (1995) 77-80. cited by examiner.

Primary Examiner: Wilson; James O.
Assistant Examiner: Ward; Paul V.
Attorney, Agent or Firm: Bednarek; Michael Pillsbury Winthrop Shaw Pittman LLP

Claims



What is claimed is:

1. A process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection, comprising: lentinan 0/50 1.40 parts by weight taken and dissolved in alkali solution 20 70 parts by weight, the concentration of alkali solution is 0.5 1.0 mol/L, and then acid solution is added to neutralize the pH to 6.0 8.0, thereafter, mixing with 50 140 parts by weight of lyophilized excipient, filtered to eliminate bacteria, subpackaged into an ampoule or bottle, sealed after lyophilization and dried to obtain the final product.

2. A process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, comprising: 0.70 1.40 parts by weight of lentinan taken and dissolved in 20 60 parts by weight of alkali solution, the concentration of alkali solution is 0.5 1.0 mol/L, and then acid solution is added to neutralize the pH to 6.0 8.0, thereafter, mixing with 70 140 parts by weight of lyophilized excipient, filtered to eliminate bacteria, subpackaged into an ampoule or bottle, and sealed after lyophilization.

3. A process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, comprising: 0.70 1.40 parts by weight of lentinan taken and dissolved in 20 60 parts by weight of alkali solution, the concentration of alkali solution is 0.5 1.0 mol/L, and then acid solution is added to neutralize the pH to 6.0 8.0, thereafter, mixing with 40 120 parts by weight of lyophilized excipient, filtered to eliminate bacteria, subpackaged into an ampoule or bottle, and sealed after lyophilization.

4. The process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, wherein said lyophilized excipient is selected from the group consisting of mannitol, glucose, sucrose and lactose.

5. The process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, wherein said lyophilized excipient is mannitol.

6. The process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, wherein said alkali is sodium hydroxide.

7. The process of preparing an aseptic antineoplastic lyophilized powder of lentinan for injection according to claim 1, wherein said acid is hydrochloric acid.
Description



The present invention relates to a biological response modifier (BRM) and the process of preparing thereof, especially, relates to an aseptic antineoplastic lyophilized powder of lentinan for injection and the process of preparation thereof.

Lentinus edodes contains multifold components such as protein, heteropolysaccharide and lentinan etc. Lentinan is a kind of polysaccharides which was extracted, separated and purified from lentinus edodes entity by Japanese scholar Chihara, G. the primary structure of which is glucose with the principal chain of .beta.-(1-3)glucose and side chain of .beta.-(1-6)glucose. According to the report, lentinan is a kind of BRM with strong inhibition to several cancers and prophylactic effect to the chemical carcinogen, virus carcinogen, especially to the micrometastasis after operation. At the same time lentinan has many virtues such as small dosage of administration, little side effect and usage safety. Japanese Health Ministry granted lentinan as a new antineoplastic drug to appear on market in 1985. China has imported the Lyophilized powder of lentinan for injection from Japanese Atinomoto and applied it in clinic since 1988. However the formula of Lyophilized powder of lentinan incorporated from Japan is composed of lentinan, dextran and mannitol. As a kind of product of fermentation, when used in clinic, dextran has been found in several cases that leading to death as its anaphylactic shock.

Chinese Patent Application CN-96116294.5 has disclosed a kind of lentinan injection and the process of preparing thereof. Firstly, dissolve the lentinan in sodium hydroxide solution, then add citrate acid to adjust the pH, and achieve the lentinan injection by filtration and disinfection. It may be effective, but it is different from the present invention in formulation dosage form, molecular weight determination and its distribution of the main product.

It is an object of the present invention to provide a lyophilized powder of lentinan without ingredient that can produce side effect.

It is another object of the present invention to provide a process of preparing lyophilized powder of lentinan without ingredient that can produce side effect.

It is still an object of the present invention to provide a lyophilized powder of lentinan without dextran.

All these and the other objects of the present invention will be illuminated in detail by further description in the following.

Aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention is substantially composed of: 0.50.about.1.40 parts by weight of lentinan, 50.about.140 parts by weight of lyophilized excipient.

Furthermore, the aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention is substantially composed of: 0.70.about.1.40 parts by weight of lentinan, 70.about.140 parts by weight of lyophilized excipient.

The aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention is also substantially composed of: 0.80.about.1.20 parts by weight of lentinan, 80.about.120 parts by weight of lyophilized excipient.

If necessary, the aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention could also be added to other acceptable or mixable additives and therapeutic drugs in medicine. Of course, these additives and therapeutic drugs will not damage the effect of lentinan, and absolutely without dextran.

If necessary, it could also be added to or mixed with other antineoplastic. Preferably, the antineoplastic and auxiliary can be bear bile powder, Redsedum, Ginseng, American ginseng, Chinese cater pillar fungus, Lucid ganoderma and Saussurea involucrate and so on.

The lyophilized excipient of aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention can be any one of mannitol, glucose, sucrose or lactose, preferably mannitol. If necessary and possible, the mixture of two or three selected from mannitol, glucose, sucrose or lactose also can be used.

The process of preparing aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention can include the following steps: 0.50.about.1.40 parts by weight of lentinan was taken and dissolved completely in the 20.about.70 parts by weight of alkali solution, the concentration of alkali solution is 0.5.about.1.0 mol/L, and then acid solution was added to neutralize the pH of the solution to 6.0.about.8.0, then mixed with 50.about.140 parts by weight of lyophilized excipient again, filtered to eliminate the bacteria, subpackaged into ampoule or glass bottle, sealed after lyophilized.

Furthermore, the process of preparing the aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention can also include the following steps: 0.70.about.1.40 parts by weight of lentinan was taken and dissolved completely in the 20.about.60 parts by weight of alkali solution, the concentration of alkali solution is 0.5.about.1.0 mol/L, and then acid solution was added to neutralize the pH of the solution to 6.0.about.8.0, then mixed with 70 140 parts by weight of lyophilized excipient again, filtered to eliminate the bacteria, subpackaged into ampoule or glass bottles, sealed after lyophilized.

The process of preparing the aseptic antineoplastic lyophilized powder of lentinan for injection can also include the following steps: 0.80.about.1.20 parts by weight of lentinan was taken and dissolved completely in the 20.about.80 parts by weight of alkali solution, the concentration of alkali solution is 0.5.about.1.0 mol/L, and then acid solution was added to neutralize the pH of the solution to 6.0.about.8.0, then mixed with 40.about.120 parts by weight of lyophilized excipient again, filtered to eliminate the bacteria, subpackaged into ampoule or glass bottle, sealed after lyophilized.

In the process of preparing aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention, the applied lyophilized excipient could be one of mannitol, glucose, sucrose or lactose, preferably mannitol. The applied alkali is sodium hydroxide and the applied acid is hydrochloric acid.

In the process of preparing aseptic antineoplastic lyophilized powder of lentinan for injection of the present invention, lentinan is mixed evenly with lyophilized excipient, and then filtered to eliminate the bacteria, determining the content (the content determined by the classical anthrone-sulfuric process), filled into the ampoule or glass bottle, lyophilize, sealed or gland bushed, leak checked, paste labeled. The procedures before sealed or gland bushed should be proceeded under asepsis condition.

The applied lentinan of the present invention includes single lentinan and multi-component lentinan, which are well-known in the prior art and can be obtained from market. Furthermore, the extraction, separation, purification of lentinan could be referred to Nature 1965, 222, 687 8 and CN-94115876 and the other patent or non-patent documents. These documents mentioned above are incorporated into the present invention herein.

The lyophilized powder of lentinan for injection of the present invention is used before operation or before chemotherapy, 1.about.2 mg each time, twice a week; or 2 mg each time, once or twice a week. When applied, the lyophilized powder of lentinan for injection should be dissolved in 250 ml saline or glucose solution, and administered by phleboclysis. When treating the malignant pleural effusion and ascites, the dosage is 4 8 mg each time by intracavitary. Specific case should obey the doctor's prescription.

The lyophilized powder of lentinan for injection of the present invention has been tested in clinic and its clinic effect is definite, the stability of preparation is very good and because it does not contain the dextran that could bring the side effect of anaphylaxis, its application in clinic is more safety. Moreover, because it does not containing dextran in the lyophilized powder of lentinan, its content determination need not separation the dextran by special column chromatography equipment and the classical anthrone-sulfuric process can be applied directly, which make the content determination more accurate and simple.

I. The Molecular Weight, Molecular Formula, Chemical Structural Formula of the Product of the Present Invention

1. The Determination of Molecular Weight

By high performance gel permeation chromatography and universal correction curve, most of its molecular weight is determined to be between 400,000 and 800,000 Dalton. 2. Carbon-nuclear Magnetic Resonance Spectrum (Tab. 1)

TABLE-US-00001 TAB. 1 Sample of C Lentinan Lentinan.sup.(6) Analysis 1 104.6 104.6 B-D- (1 3 ) glucose 2 74.5 74.3 B-D- (1 3 ) glucose 3 87.7 87.7 B-D- (1 3 ) glucose 4 70.2 70.2 B-D- (1 3 ) glucose 5 77.8 77.9 B-D- (1 3 ) glucose 6 62.5 62.5 B-D- (1 3 ) glucose 1' 104.9 104.6 B-D- (1 6 ) glucose 6' 71.5 71.5 B-D- (1 6 ) glucose

3. Figure of Infra-red Spectrum (FIG. 1) 4. Molecular Formula

The result of the trace of element analysis indicates that its molecular formula is (C.sub.6H.sub.10O.sub.5).sub.n 5. Chemical Structural Formula

Combined the chemical reaction such as Periodic acid reaction, Smith degradation reaction with optical spectrum analysis, the primary structure of the lentinan displays as the following:

##STR00001## II. Result and Conclusion of the Stability of the Preparation

Tested by the influencing factor test such as the high-temperature test (40.degree. C., 60.degree. C., 80.degree. C.), high humidity test (RH92.5%, RH75%, 25.degree. C.) and light irradiation test (4000 Lx), appearance character, clarity after dissolving, pH value, content, impurity and asepsis test of the product of the present invention meet the request.

After three-month speed-up test (40.degree. C. RH 75%), the review result shows that the appearance character, clarify after dissolving, pH value, content, impurity and asepsis test of the product of the present invention meet the request.

The product of the present invention was observed and analyzed respectively in 1, 3, 5, 12, 18 and 24 month at room temperature after being prepared. By way of the periodical check of the samples, all items meet the request. So the effective period is at least two years.

All raw materials and excipient of the present invention could be obtained from market. The applied excipients are solid for injectable grade except pointing out specially.

The following examples will further indicate the present invention. Although the examples are limited in description, it can not limit the extent of the application of the present invention.

In the present invention, all the portions and quantities are the unit of weight based on the gross weight other than mentioned specially.

EXAMPLE 1

The example uses clinical trial phase II and III to prove the excellent effect of the lyophilized powder of lentinan for injection of the present invention.

I. Clinical Trial of the Phase II:

The double-blind process and stochastic process are adopted to proceed the clinical trial of the phase II via the hospital appointed by nation. Combined chemotherapy and placebo (lyophilized powder) being the controlling group and combined chemotherapy and lyophilized powder of lentinan being the testing group, 240 patients with different kinds of cancer are tested. The result illuminates that there are CR+PR 67 examples in the 108 examples of the testing group, and the total effective rate is 62%; CR+PR 44 examples in 104 examples of the controlling group, and the total effective rate is 43.2%. Compared both result, the P<0.01, in which the total effective rate of the gastric cancer in the testing group is 56.6%, the total effective rate of the controlling group is 19.4%, the P<0.01, the total effective rate of the non-small cell lung cancer (NSCLC) in the testing group is 33.3%, the total effective rate of the controlling group is 19.5%, the P<0.01, the total effective rate of the controlling group is 11.5%, the P<0.05. Compared the effect of pre-treatment and post-treatment, the variation rate of lymphocytic cell conversion, NK cytoactive and the rate of T.sub.4/T.sub.8 of the testing group are remarkably higher than those of the controlling group, the P<0.01. The effective rate of preliminary using the lentinan to treat the malignant pleural effusion and ascites is 76.5% (13/17), which is similar to that of the foreign literature.

II. The Clinical Trial of the Phase III:

Under the leading of Chinese Medical Association, the Cancer Hospital of Zhongshan Medical University as the responsible hospital, about 40 hospitals in China take part in the clinical trial of the phase III and examines further the clinical effect and the adverse reaction of the lentinan. They complete the 1106 evaluable cases, including 1047 cases with systemic administration and 59 cases with malignant pleural effusion and ascites. 1. The total effective rate of the combined chemotherapy group (565 cases) is 41.1%, Compared with the controlling group (301 cases) which is 25.2%, the effective rate of the two groups are of significant difference (P<0.01), in which the total effective rate of gastric cancer and NSCLC are obviously higher than the controlling group (P<0.01). The same kind of Japanese products company have the chemotherapy enhancement effect of NSCLC hasn't been reported before. 2. malignant pleural effusion and ascites: the total effective rate is 52.5% in 59 cases. 3. At the same time, this test also observes the patients' variation of cellular immune function, and the result shows that the three testing index (NK cytoactive, T.sub.3, T.sub.4/8) are obviously higher than that of the controlling group, and all kinds of main cases display that the lentinan's value enhances the function of cellular immunity. 4. Active State (PS)

There are 1647 cases in the group. The PS of 28.5% patients in the combined chemotherapy group (565 cases) have been improved after treatment (post-treatment compared with pretreatment, there exists significant difference, P<0.01), yet in the controlling group, only 6.8% patient's PS have been improved (compared with pretreatment, there have not significant difference after treatment, P>0.05), compared with the controlling group, the testing group have significant difference (P<0.01). 5. Reducing the Side-effect of Radiotherapy and Chemotherapy

Combined chemotherapy, post-operation combined chemotherapy: The falling incidence rate of WBC.P.sub.1 in testing group is significantly lower than that of the controlling group (P<0.01). Gastrointestinal toxicity, liver function lesion in the testing group is also lower than that of the controlling group (P<0.01). The incidence rate of nausea vomitus in testing group is significantly lower than that of the controlling group (P<0.01). It has not been reported in clinic that the like products of Japanese Atinomotocompany have this very effect. 6. Side-effect

Only three cases of side-effect occurred, occupying 0.27% among the 1121 cases that applied lentinan systemically, including two cases of facial flush, one case of chest discomfort, which could restore in short time after slowing the drip speed or withdrawing drug. In 469 cases of the clinical trial of the phase II, III of Japanese product, 32 cases of side-effect occured, occupying 6.8%.

EXAMPLE 2

2.00 g lentinan material for injection (purity 98% was taken, 60 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8 7.0 1000 ml commercial 20% mannitol injection solution was added, and stirred equally, aseptic filtrated, the content (the content determination used the classical anthrone-sulfuric process) was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 1 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, sealed, leak checked, eye checked, labeled and the end product was achieved at last.

EXAMPLE 3

3 g lentinan for injection was taken, dissolved fractionally in 100 ml 0.8M sodium hydroxide solution when stirred until completely dissolved, and then 0.8M hydrochloric acid was slowly added to neutralize the pH of the solution to 7.0 7.2. Getting 300 g commercial mannitol for injection was taken, and 1600 ml water for injection was added and to dissolve it by heating, then 0.1% W/V activated carton for injection was added and heated for 15 min at 85.degree. C., filtered by using No. 3 sand core filter candle when cooled to 60.degree. C., then the lentinan solution was added into the filtering solution, thereafter proceed asepsis filtration by using the filter membrane, the content was determined, then water for injection was added to achieve the concentration that each 2 ml solution contain 1.5 mg lentinan, the ampoule was filled to 2 ml/ampoule, moved into the freezing room to be lyophilized and dried, then it was taken out and the ampoule or bottle was sealed, leak checked and labeled, and the end product was achieved at last.

EXAMPLE 4

4.00 g lentinan material for injection (purity 98%) (obtained from market) was taken, 120 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8 7.0. 400 g mannitol injection was added, and water for injection was added until the total volume was 3200 ml, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 2 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 5

2.00 g lentinan material for injection (purity 98%) was taken, 50 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Suitable amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8 7.0. 200 g glucose for injection was added, and 1800 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 2 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 6

2.00 g lentinan material for injection (purity 98%) was taken, 60 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Suitable amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8.about.7.0. 200 g lactose for injection was added, and 3200 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 1 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 7

6.00 g lentinan material for injection (purity 98%) was taken, 180 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8.about.7.0. 400 g mannitol for injection was added, and 3200 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 3 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decreated, sealed, leak checked, eye checked and labeled.

EXAMPLE 8

6.00 g lentinan material for injection (purity 98%) was taken, 180 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 8.8.about.7.0. 400 g glucose for injection was added, and 3200 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 3 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 9

8.00 g lentinan material for injection (purity 98%) was taken, 240 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8 7.0. 400 g sucrosem for injection was added, and 3200 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 4 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 10

8.00 g lentinan material for injection (purity 98%) was taken, 240 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred equally. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8 7.0. 400 g glucose for injection was added, and 3100 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 4 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decrated, sealed, leak checked, eye checked and labeled.

EXAMPLE 11

8.0 lentinan material for injection (purity 98%) was taken, 240 ml 1M sodium hydroxide solution was added. The lentinan was swelt naturally, then stirred to make them dissolve completely. Small amount of water for injection was added to dilute, then stirred again. 1M hydrochloric acid was added to neutralize the pH of the solution to 6.8.about.7.0. 400 g lactose for injection was added, and 3100 ml water for injection was added, stirred equally and aseptic filtrated, the content was determined. Water for injection was added to achieve the concentration that each 2 ml solution contains 4 mg lentinan, subpackaged into 2 ml/ampoule or bottle, then lyophilized and dried, decorated, sealed, leak checked, eye checked and labeled.

EXAMPLE 12

Besides using lentinan for injection 8.0 g (purity 98%), adding 240 ml 0.8M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solutions 6.0.about.6.2, and then adding mannitol for injection 400 mg and adding water for injection 3100 ml , the rest is the same as example 11.

EXAMPLE 13

Besides using lentinan for injection, 4.0 g (purity 98%), adding 200 ml 0.8M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution pH to 6.3 6.4, and then adding lactose for injection 200 g, adding water for injection 3100 ml, the rest is the same as example 5.

EXAMPLE 14

Besides using lentinan for injection 4.0 g (purity 98%), adding 50 ml 0.8M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 6.5 6.6, and then adding sucrose for injection 200 g, adding water for injection 3100 ml, the rest is the same as example 4.

EXAMPLE 15

Besides using lentinan for injection 1.0 g (purity 98%), adding 50 ml 0.8 M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 6.0 6.2, and then adding mannitol for injection 200 g, adding water for injection 3100 ml, the concentration being 0.5 mg each 2 ml, the rest is the same as example 4.

EXAMPLE 16

Besides using lentinan for injection 1.0 g (purity 98%), adding 50 ml 1M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 7.0 7.2, and then adding glucose for injection 200 g, adding water for injection 3200 ml, the rest is the same as example 15.

EXAMPLE 17

Besides using lentinan for injection 1.0 g (purity 98%), adding 50 ml 0.8M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 7.4 7.6, and then adding sucrose for injection 200 g, adding water for injection 3200 ml, the rest is the same as example 15.

EXAMPLE 18

Besides using lentinan for injection 1.0 g (purity 98%), adding 50 ml 0.8M sodium hydroxide solution, adding citric acid solution to adjust the pH of the solution to 7.6 7.8, and then adding lactose for injection 200 g, adding water for injection 3200 ml, the rest is the same as example 15.

EXAMPLE 19

Besides using lentinan for injection 2.0 g (purity 98%), adding 60 ml 0.8M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 7.8.about.8.0, and then adding mannitol for injection 200 g, adding water for injection 3100 ml, the rest is the same as example 6.

EXAMPLE 20

Besides using lentinan for injection 2.0 g (purity 98%), adding 50 ml 1.0M sodium hydroxide solution, adding hydrochloric acid solution to adjust the pH of the solution to 7.8 8.0, and then adding glucose for injection 100 g, adding mannitol for injection 100 g, adding water for injection 3100 ml, the rest is the same as example 6.

EXAMPLE 21

Besides using lentinan for injection 2.0 g (purity 98%), adding 100 ml 1.0M sodium hydroxide solution, adding hydrochloride acid solution to adjust the pH of the solution to 7.0.about.7.1, and then adding lactose for injection 100 g, adding mannitol for injection 100 g, adding water for injection 3000 ml, the rest is the same as example 6.

In the present invention, the examples are only used to illuminate. But they can not limit the extent of the claim of the present invention, any improvement and alternation should be calculated into the extent of the present invention and be limited by the claim of the present invention.

*


Free Web Sudoku Puzzles.
Solve with your browser.
    3 1 4     5  
            2   1
    5 9       3  
        6 3     7
  6           8  
9     4 7        
  5       8 6    
2   7            
  8     2 1 4    
What is it?



Add Your Site · Terms Of Service · Privacy Policy


DISCLAIMER
Linkgrinder is a free service that searches the Internet and indexes all files found so that you may search quickly and easily for shared files. These files are created and made available individually by users whose identity we are not aware of and who we have no control over. In essence we function like a search engine tool; these files ARE NOT STORED OR SERVED BY OUR NETWORK. We are not responsible for any materials obtained by using our service. We do not monitor any of the contents of these files. These files may contain viruses, illegal materials, materials inappropriate for minors, offensive files and the like. BY USING OUR SERVICE, YOU ASSUME FULL RESPONSIBILITY FOR DOWNLOADING THESE MATERIALS AND WILL INDEMNIFY US FOR ANY DAMAGES THAT MAY BE INCURRED.

For More Specific Information VIEW OUR TERMS OF SERVICE.

Thank you and Enjoy!